异动解读｜雅培盘中上涨3.21%，结直肠癌血液筛查测试获FDA批准利好延续

行情直击08-03

8月3日，雅培盘中上涨3.21%，报108.08美元/股，成交额9532.12万美元。

消息面上，FDA于近日正式批准雅培与Freenome合作研发的SimpleScreen CRC血液基础结直肠癌筛查测试，该测试面向45岁及以上平均风险成年人群。根据双方商业协议，雅培将于今年秋季在美国独家推广商业化该检测产品，并向Freenome支付1亿美元里程碑付款。这一非侵入性筛查技术的获批标志着雅培诊断业务板块获得重要增长引擎，叠加此前与ALZpath达成阿尔茨海默病诊断全球授权协议，公司在精准诊断领域布局持续加速，市场情绪积极。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1163618632?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-03 21:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163618632","market":"hk","top_or_hot":-1,"title":"异动解读｜雅培盘中上涨3.21%，结直肠癌血液筛查测试获FDA批准利好延续","media":"行情直击","content":"<p><p>8月3日，雅培盘中上涨3.21%，报108.08美元/股，成交额9532.12万美元。</p><p>消息面上，FDA于近日正式批准雅培与Freenome合作研发的SimpleScreen CRC血液基础结直肠癌筛查测试，该测试面向45岁及以上平均风险成年人群。根据双方商业协议，雅培将于今年秋季在美国独家推广商业化该检测产品，并向Freenome支付1亿美元里程碑付款。这一非侵入性筛查技术的获批标志着雅培诊断业务板块获得重要增长引擎，叠加此前与ALZpath达成阿尔茨海默病诊断全球授权协议，公司在精准诊断领域布局持续加速，市场情绪积极。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜雅培盘中上涨3.21%，结直肠癌血液筛查测试获FDA批准利好延续</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜雅培盘中上涨3.21%，结直肠癌血液筛查测试获FDA批准利好延续\n</h2>\n\n<h4 class=\"meta\">\n\n2026-08-03 21:57 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月3日，雅培盘中上涨3.21%，报108.08美元/股，成交额9532.12万美元。消息面上，FDA于近日正式批准雅培与Freenome合作研发的SimpleScreen CRC血液基础结直肠癌筛查测试，该测试面向45岁及以上平均风险成年人群。根据双方商业协议，雅培将于今年秋季在美国独家推广商业化该检测产品，并向Freenome支付1亿美元里程碑付款。这一非侵入性筛查技术的获批标志着雅培诊断业务...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABT","symbol_name":"雅培","start_time":0,"source_url":"","article_id":"1163618632","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163618632","pubTimestamp":1785765435,"columns":[{"name":"产品发布","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"8月3日，雅培盘中上涨3.21%，报108.08美元/股，成交额9532.12万美元。消息面上，FDA于近日正式批准雅培与Freenome合作研发的SimpleScreen CRC血液基础结直肠癌筛查测试，该测试面向45岁及以上平均风险成年人群。根据双方商业协议，雅培将于今年秋季在美国独家推广商业化该检测产品，并向Freenome支付1亿美元里程碑付款。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ABT":"雅培"},"translate_title":"Interpretation of the change | Abbott rose 3.21% in the intraday session, and the colorectal cancer blood screening test was approved by the FDA, and the positive continues","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT":1},"content_text":"8月3日，雅培盘中上涨3.21%，报108.08美元/股，成交额9532.12万美元。消息面上，FDA于近日正式批准雅培与Freenome合作研发的SimpleScreen CRC血液基础结直肠癌筛查测试，该测试面向45岁及以上平均风险成年人群。根据双方商业协议，雅培将于今年秋季在美国独家推广商业化该检测产品，并向Freenome支付1亿美元里程碑付款。这一非侵入性筛查技术的获批标志着雅培诊断业务板块获得重要增长引擎，叠加此前与ALZpath达成阿尔茨海默病诊断全球授权协议，公司在精准诊断领域布局持续加速，市场情绪积极。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163618632","isCrawlerRequest":true}